Skip to main content Accessibility help
×
Home
Hostname: page-component-99c86f546-t82dr Total loading time: 2.711 Render date: 2021-11-30T18:00:35.633Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Eslicarbazepine Acetate

Published online by Cambridge University Press:  01 June 2018

Philip N. Patsalos
Affiliation:
UCL Institute for Neurology
Erik K. St Louis
Affiliation:
Mayo Clinic
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Almeida, L, Falcao, A, Maia, J, Mazur, D, Gellert, M, Soares-da-Silva, P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2–093) in healthy elderly and young subjects. Journal of Clinical Pharmacology 2005; 45: 10621066.CrossRefGoogle ScholarPubMed
Almeida, L, Potgieter, JH, Maia, J, Potgieter, MA, Moto, F, Soares-da-Silva, P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. European Journal of Clinical Pharmacology 2008; 64: 267273.CrossRefGoogle ScholarPubMed
Almeida, L, Soares-da-Silva, P. Eslicarbazepine acetate (BIA-2–093). Neurotherapeutics 2007; 4: 8896.CrossRefGoogle Scholar
Elger, C, Halasz, P, Maia, J, Almeida, L, Soares-da-Silva, P, on behalf of the BIA-2093–301 Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo controlled, parallel-group phase III study. Epilepsia 2009; 50: 454463.CrossRefGoogle ScholarPubMed
Falcão, A, Fuseau, E, Nunes, T, Almeida, L, Soares-da-Silva, P. Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacody-namic analyses. CNS Drugs 2012; 26: 7991.CrossRefGoogle ScholarPubMed
Gil-Nagel, A, Elger, C, Ben-Menachem, E, Halász, P, Lopes-Lima, J, Gabbai, AA, Nunes, T, Falcão, A, Almeida, L, da-Silva, PS. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia 2013; 54: 98107.CrossRefGoogle ScholarPubMed
Gil-Nagel, A, Lopes-Lima, J, Almeida, L, Maia, J, Soares-da-Silva, P, on behalf of the BIA-2093–303 Investigators Study Group. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurologica Scandinavica 2009; 120: 281287.CrossRefGoogle ScholarPubMed
Johannessen Landmark, C, Patsalos, PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Reviews in Neurotherapeutics 2010; 10: 119140.CrossRefGoogle ScholarPubMed
Meis, J, Almeida, L, Falcao, A, Soares, E, Mota, F, Potgieter, MA, Potgieter, JH, Soares-da-Silva, P. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. International Journal of Clinical Pharmacology and Therapeutics 2008; 463: 119130.Google Scholar
Nunes, T, Rocha, JF, Falcão, A, Almeida, L, Soares-da-Silva, P. Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers. Epilepsia 2013; 54: 108116.CrossRefGoogle ScholarPubMed
Patsalos, PN. Antiepileptic drug interactions: a clinical guide, 3rd edition. Springer, London, UK; 2016.CrossRefGoogle Scholar
Patsalos, PN, Berry, DJ. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. Expert Opinion in Pharmacotherapy 2012; 13:699715.CrossRefGoogle ScholarPubMed
Perucca, E, Elger, C, Halász, P, Falcão, A, Almeida, L, Soares-da-Silva, P. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. Epilepsy Research 2011; 96: 1321329.CrossRefGoogle ScholarPubMed
Villanueva, V, Bermejo, P, Montoya, J, Toledo, M, Gómez-Ibáñez, A, Garcés, M, Vilella, L, López-González, FJ, Rodriguez-Osorio, X, Campos, D, Martínez, P, Giner, P, Zurita, J, Rodríguez-Uranga, J, Ojeda, J, Mauri, JA, Camacho, JL, Ruiz-Giménez, J, Poza, JJ, Massot-Tarrús, A, Galiano, ML, Bonet, M. EARLY-ESLI study: long-term experience with eslicarbazepine acetate after first monotherapy failure. Acta Neurologica Scandinavica 2017; 136: 254264.CrossRefGoogle ScholarPubMed

Send book to Kindle

To send this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Send book to Dropbox

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Dropbox.

Available formats
×

Send book to Google Drive

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Google Drive.

Available formats
×